In an era when antibiotic resistance has become one of the main threats to humanity, medical science is increasingly turning its attention to alternative methods of fighting infections. One such approach is personalized phage therapy , which relies on the use of bacteriophages , viruses that destroy pathogenic bacteria . Unlike antibiotic treatment, this therapy is individualized—it takes into account the specific patient's situation, identifies the specific microbe, and even takes into account dynamic changes in the microbial flora.

Why is phage therapy personalized?

The essence of personalized phage therapy is that phages are selected for each patient's treatment to precisely destroy the specific bacterial strain causing the disease. This is not a "broad-spectrum" therapy like most antibiotics, but a highly precise weapon capable of acting selectively, without affecting the body's beneficial microflora.

In practice, it works like this: biomaterial (manure, sputum, urine, etc.) is collected from the patient, and the infectious agent is isolated in the laboratory. This pathogen is then tested for sensitivity to existing bacteriophages—or new phage strains are created if a suitable one is not available in the bank. This approach requires collaboration between physicians, microbiologists, pharmacologists, and laboratories, which results in a unique treatment model— a drug tailored specifically to the individual .

Integration into modern medicine: difficult, but possible

Medical institutions around the world are gradually beginning to implement phage-based therapeutic approaches. Some European countries (France, Poland, Germany), as well as the United States and Canada, already have clinical phage therapy programs in place, particularly for patients with recurrent or chronic infections who are not treated with antibiotics.

Scientists are working to create phage banks containing hundreds, even thousands, of strains suitable for treating various bacteria. At the same time, genetic editing of phages is developing, allowing them to be "reprogrammed" to target new targets. In the future, this will enable the development of phage therapy platforms that will automatically select the appropriate bacterial viruses based on the pathogen's genetic profile—similar to how DNA sequencing is currently used in cancer diagnostics.

Strengths and weaknesses of personalized therapy

The advantages of personalized phage therapy are obvious:

• High specificity : phages kill only harmful microorganisms without disturbing the balance of microbiota.
• Minimum side effects : unlike antibiotics, bacteriophages do not cause allergies and do not cause dysbacteriosis.
• Evolutionary capacity : These viruses can change along with bacteria, reducing the risk of resistance.
• Reusability : The same phage can be used again when reinfected with the same strain.

However, there are also disadvantages that hinder the widespread implementation of the method:

• Manufacturing complexity : Personalized phages require laboratory cultivation and sterile quality control.
• Regulatory barriers : In many countries, bacteriophages are not registered as official medicines.
• Preparation time : It can take several days from sample collection to preparation of the drug – in critical cases, this is precious time.

The solution to these problems is seen in the creation of global phage banks , accelerated registration procedures, and the development of mobile phage laboratories. Such initiatives are already gradually being implemented.

Georgia: the capital of phage therapy

Georgia remains the world's most renowned center for personalized phage therapy. Since the 1920s, the Eliava Institute has been operating there—a unique scientific institution that has accumulated vast experience in treating infections with phages over the course of a century. Even during Soviet times, when phage therapy was virtually forgotten in the Western world, Georgia continued to develop it.

Today, patients from all over the world—the USA, Germany, Japan, Canada, and Australia—fly to Tbilisi in hopes of curing severe, antibiotic-resistant chronic infections . These include patients with osteomyelitis, resistant urinary tract infections, and postoperative complications.

Georgia is a unique example of a country where phage therapy is officially recognized and legalized , and its use is integrated into clinical practice. The Eliava Institute also actively collaborates internationally, training personnel, developing joint protocols with Western clinics, and promoting global access to personalized treatment.

Where else do they treat with phages?

Besides Georgia, phage therapy is actively used in:

• Poland - the leader in this field is the Hirschfeld Institute in Wroclaw, where the Phage Therapy Center has been operating since 2005;
• France - clinical trials within the framework of the national Phagoburn program;
• USA - a series of studies involving Stanford University and the FDA;
• India and Israel , where national phage banks are being created.

But in most countries, the method remains experimental or is only available on an individual basis through compassionate use programs.

Personalized phage therapy is not just an alternative to antibiotics, but a revolutionary strategy that takes into account the uniqueness of each patient. It is based on precision, intelligence, and the collaboration of science and medicine. This treatment requires more resources and effort, but it offers a chance where other methods fail. And although the road remains long, the first steps have already been taken.